Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aytu BioPharma, Inc. - Common Stock (NQ: AYTU )

1.640 -0.050 (-2.96%)
Streaming Delayed Price Updated: 3:59 PM EST, Jan 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aytu BioPharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results
Via ACCESSWIRE
Aytu BioPharma's Earnings: A Preview
Via Benzinga
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year
Via ACCESSWIRE
Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023
Via ACCESSWIRE
Biggest Short Squeeze Stocks Of The Week: Biotech Stocks Dominate, A Bitcoin-Related Stock Moves Up Leaderboard
Potential short squeeze plays gained steam in 2021, continued throughout 2022 and remained a focus of traders looking for the next big move. High short interest and steep borrowing costs are among the... 
Via Benzinga
Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement
Via ACCESSWIRE
Aytu BioPharma Inc. (NASDAQ: AYTU) Near the Top of Equities by Percentage Gain on 9/28
Via Investor Brand Network
Aytu BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023
Via ACCESSWIRE
Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why CarMax Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Bionomics Limited (NASDAQ: BNOX) shares jumped 308% to $4.00 after the company announced the ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant... 
Via Benzinga
Earnings Outlook For Aytu BioPharma
Via Benzinga
Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market
Via ACCESSWIRE
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Earnings Scheduled For September 27, 2023
Companies Reporting Before The Bell • Paychex (NASDAQ:PAYX) is projected to report quarterly earnings at $1.12 per share on revenue of $1.29 billion. 
Via Benzinga
Aytu BioPharma to Report Fourth Quarter and Fiscal 2023 Financial Results on September 27, 2023
Via ACCESSWIRE
Aytu BioPharma to Present at LD Micro Main Event XVI Conference
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Aytu BioPharma: Q3 Earnings Insights
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2023
Via Benzinga
Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline
Dallas, Texas--(Newsfile Corp. - August 8, 2023) - Stonegate is pleased to announce the... 
Via Newsfile
Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian Authority
Via ACCESSWIRE
Aytu BioPharma Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement
Via ACCESSWIRE
Star Equity Holdings And 2 Other Stocks Under $2 Insiders Are Aggressively Buying
The Dow Jones closed higher by over 400 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Aytu to Participate in the Maxim Group Virtual Healthcare Conference
Via ACCESSWIRE
Aytu BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New Director
Via ACCESSWIRE
AYTU Stock Earnings: Aytu Misses EPS, Revenue Estimates
AYTU stock earnings show Aytu Biopharma missing earnings per share and revenue estimates for the fiscal third quarter. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.